Is soaring on earnings: they beat and raise. Their signature disease test outperformed and boasts a total addressable market of $7 billion. They are tops in this space. Great managers.
A biotech that does, among other things, cancer testing which is very accurate.. She just bought it. Is growing fast and expects it to be cash-flow positive this year.
Trimmed it because it moved up 145% the past year. They have a great franchise in cancer detection recurrence. Likes it long-term.